Objective To examine the effect of diagnosis year, defined as contemporary (2010–2014),
intermediate (2006–2009) and historical (2001–2005) on cancer-specific mortality (CSM) in …

Conclusion Whatever the modest progress made for a small number of patients with MRCC,
the majority of patients will die within 5 years of diagnosis of MRCC. Therefore, there is a …

Background Targeted therapies improve survival in metastatic renal cell carcinoma (mRCC).
However, survival patterns can be divergent, and patients at the 2 extremes of the survival …

The introduction of molecularly targeted therapies (TTs) has transformed the management of
metastatic renal cell carcinoma (mRCC). Within a relatively short period of time, systemic …

BACKGROUND. The majority of metastatic renal cell carcinoma (mRCC) clinical trials that
examined targeted agents used progression‐free survival (PFS) as the primary endpoint …

For many years, therapy for metastatic renal cell carcinoma (mRCC) was limited to a single
line of cytokine therapy with either interferon or interleukin-2. Relatively recently, the novel …

The treatment of metastatic renal cell carcinoma (mRCC) has been changed by the
introduction of targeted agents. Consideration of individual patient factors, such as previous …

Background With the advent of small-molecule “targeted” therapies, the prevailing treatment
paradigm for metastatic renal cell carcinoma (mRCC) is that all patients who are able to …

Background: Over the past few years, significant advancements have been achieved in the
front-line treatment of metastatic renal cell carcinomas (mRCCs). However, most patients will …

Multiple promising agents are available in the treatment of mRCC. The appropriate
sequencing of agents in the treatment of mRCC may become further elucidated by future …